GU Cancers 2020 | UC breakthroughs: personalized therapy and immunotherapies

Name: UC breakthroughs: personalized therapy and immunotherapies
Uploaded: 2020-02-15T15:34:15Z
Description: Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, gives his thoughts on some of the biggest breakthroughs in urothelial cancer (UC). Specifically discussed is personalized therapy, immunotherapy and the evolving role of PD-L1 testing in metastatic urothelial carcinoma. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Thomas Powles • 15 Feb 2020

GU Cancers 2020

Bladder Cancer Genitourinary Cancer

JAVELIN

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, gives his thoughts on some of the biggest breakthroughs in urothelial cancer (UC). Specifically discussed is personalized therapy, immunotherapy and the evolving role of PD-L1 testing in metastatic urothelial carcinoma. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.